# US 2026/0224499 A1 · Compositions and methods for treating pulmonary conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224499 A1
- Document ID: US20260224499A1
- Status: Published application
- Kind: A1
- Application number: 19/150,339
- Filed: 2024-02-02
- Published: 2026-08-06
- Earliest claimed: 2023-02-03
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Atta Behfar; Skylar Alexis Rizzo; Robert Vassallo; Shaohua Wang
- Web page: https://patentgrep.com/patent/US20260224499A1

## CPC

- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/44: Oxidoreductases (1)
- A61P 11/00: Drugs for disorders of the respiratory system
- C12Y 114/99003: Heme oxygenase (1.14.99.3)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition generally includes administering to the subject a therapeutic composition in an amount effective to treat the pulmonary′ condition. Generally, the therapeutic composition includes purified exosome product (PEP) exosomes and a pharmaceutically acceptable carrier. In one or more embodiments, the PEP exosomes are modified to include at least one exogenous active agent. In one or more embodiments, the therapeutic composition is formulated for delivery directly to a potion of tire pulmonary tract.

## Claims

### Claim 1

A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition, the method comprising:
administering to the subject a therapeutic composition in an amount effective to treat the pulmonary condition, the therapeutic composition comprising:
a purified exosome product (PEP) exosomes; and
a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PEP exosomes are spherical or spheroid exosomes having a diameter no greater than 300 nm.

### Claim 3 (depends on 1)

The method of claim 1, wherein the PEP exosomes are spherical or spheroid exosomes having a mean diameter of 110 nm±90 nm.

### Claim 4 (depends on 3)

The method of claim 3, wherein the PEP exosomes are spherical or spheroid exosomes having a mean diameter of 110 nm±50 nm.

### Claim 5 (depends on 4)

The method of claim 4, wherein the PEP exosomes are spherical or spheroid exosomes having a mean diameter of 110 nm±30 nm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises from 1×1010 PEP exosomes to 1×1011 PEP exosomes.

### Claim 7 (depends on 6)

The method of claim 6, wherein the composition comprises from 1.25×1010 PEP exosomes to 5×1010 PEP exosomes.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition comprises from 2.5×1010 PEP exosomes to 5×1010 PEP exosomes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the therapeutic composition is formulated for delivery to at least a portion of the subject's pulmonary tract.

### Claim 10 (depends on 9)

The method of claim 9, wherein the therapeutic composition is formulated for delivery to at least a portion of the subject's lung bed.

### Claim 11 (depends on 9, 10)

The method of claim 9 or claim 10, wherein the therapeutic composition is nebulized.

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutic composition is administered in an amount effective to decrease lung compliance (Cst), decrease mean linear intercept (Lm), increase lymphocytic infiltrates in perivascular areas, increase proportion of CD4+FOXP3+ Tregs in perivascular lymphocytes, increase proportion of CD22+ plasma cells in perivascular lymphocytes, decrease expression of inflammatory signaling pathway genes, decrease expression of fibrotic signaling genes, decrease expression of PD1/PD-L1 cancer immunotherapy genes, decrease expression of tumor microenvironment pathway genes, decrease phagosome formation, decrease expression of tumor necrosis factor (TNF), decrease expression of IL-17A-regulated pathways, decrease immune cell chemotaxis, decrease expression of NF-κB signaling pathway genes, decrease expression of senescence pathway genes, increase expression of wound healing pathway genes, decrease S100A8+ macrophages in alveolar and/or interstitial regions of the lung, decrease S100A9+ macrophages in alveolar and/or interstitial regions of the lung, increase heme oxygenase-1 (HO-1) in a whole lung lysate, decrease NF-κB p65 in a whole lung lysate, decrease caspase 8 in a whole lung lysate, decrease caspase 3 in a whole lung lysate, decrease CXCL12 transcription, increase expression of an antioxidant by alveolar epithelial cells, decrease apoptosis of alveolar epithelial cells, or any combination of two or more of the foregoing, compared to a subject to which the PEP composition is not administered.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antioxidant comprises SOD 1-3 or heme oxygenase (HO-1).

### Claim 14 (depends on 1)

The method of claim 1, wherein the PEP exosomes contain an antioxidant compound.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antioxidant compound is heme oxygenase (HO-1).

### Claim 16 (depends on 1)

The method of claim 1, wherein at least a portion of the PEP exosomes are modified to include at least exogenous active agent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the exogenous active agent comprises a polypeptide or a nucleic acid.

### Claim 18 (depends on 17)

The method of claim 17, wherein the nucleic acid is an mRNA that encodes a therapeutic polypeptide or an inhibitory RNA.
